Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 3/20 | 0.33 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 2/20 | 0.32 |
| ▸ | CA2 | P00918 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1983047 | 0.89 | ALDH1A1 (0.39) | ENPP2CA1CA2 | |
| SCHEMBL17675421 | 0.78 | MGLL (0.32) | ENPP2 | |
| SCHEMBL2300859 | 0.77 | ENPP2 (0.57) | ENPP2CA1CA2 | |
| SCHEMBL557225 | 0.76 | MEN1 (0.38) | — | |
| SCHEMBL219239 | 0.76 | CYP11B1 (0.34) | ENPP2 | |
| SCHEMBL366006 | 0.76 | CA1 (0.52) | ENPP2CA1CA2 | |
| SCHEMBL4592239 | 0.75 | PGR (0.35) | ENPP2 | |
| SCHEMBL519259 | 0.75 | ENPP2 (0.52) | ENPP2CA1CA2 | |
| SCHEMBL29427153 | 0.75 | ENPP2 (0.52) | ENPP2CA1CA2 | |
| SCHEMBL3764758 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10053453-B2 | Compounds and their use as BACE inhibitors | ASTRAZENECA AB (SE) | 2018-08-21 | — | — | US | disclosed |
| US-20170313686-A1 | COMPOUNDS AND THEIR USE AS BACE INHIBITORS | ASTRAZENECA AB (SE) | 2017-11-02 | — | — | US | disclosed |
| WO-2016055858-A1 | COMPOUNDS AND THEIR USE AS BACE INHIBITORS | ASTRAZENECA AB (SE) | 2016-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170313686-A1 | COMPOUNDS AND THEIR USE AS BACE INHIBITORS | BACE1, BACE2, APP | ENPP2 586/4885MAP3K14 2626/4885CA1 2432/4885 |
| US-10053453-B2 | Compounds and their use as BACE inhibitors | BACE1, BACE2, APP | ENPP2 586/4885MAP3K14 2626/4885CA1 2432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.